A guanidine-based coronavirus replication inhibitor which targets the nsp15 endoribonuclease and combines a direct antiviral effect with subtle boosting of interferon

Benjamin Van Loy,Eugènia Pujol,Kenichi Kamata,Xiao Yin Lee,Nikolai Bakirtzoglou,Ria Van Berwaer,Julie Vandeput,Leentje Persoons,Brent De Wijngaert,Quinten Goovaerts,Sam Noppen,Kourosh Ahmadzadeh,Juan Martín-López,Celia Escriche,Bert Vanmechelen,Besir Krasniqi,Abhimanyu K. Singh,Piet Maes,Patrick Matthys,Wim Dehaen,Jef Rozenski,Kalyan Das,Arnout Voet,Santiago Vázquez,Lieve Naesens,Annelies Stevaert

DOI: https://doi.org/10.1101/2024.09.09.611961

2024-09-09

Abstract:The approval of COVID-19 vaccines and two classes of antiviral drugs has been crucial in addressing the global health crisis caused by SARS-CoV-2. However, to prepare for future outbreaks from drug-resistant variants and novel zoonotic coronaviruses (CoVs), additional therapeutics with a distinct antiviral mechanism are needed. Here, we report a novel guanidine-substituted diphenylurea compound that suppresses CoV replication by interfering with the uridine-specific endoribonuclease (EndoU) activity of the viral non-structural protein-15 (nsp15). This compound, designated EPB-113, exhibits strong and selective cell culture activity against human coronavirus 229E (HCoV-229E) and also suppresses the replication of SARS-CoV-2. HCoV-229E viruses selected for resistance to EPB-113 carried mutations at or near the catalytic residue His250 in the nsp15 EndoU domain. EndoU is known to reduce the levels of viral dsRNA and avoid induction of type I interferon (IFN-I). Accordingly, the mutant viruses selected under EPB-113 were unable to replicate in human macrophages and were readily outcompeted by the wild-type virus upon co-infection of human fibroblast cells. This highlights the critical role of EndoU in maintaining CoV replication. By targeting nsp15, EPB-113 combines a direct antiviral effect with subtle boosting of IFN-I. Using a combination of biophysical and enzymatic assays with the recombinant nsp15 proteins from HCoV-229E and SARS-CoV-2, we discovered that EPB-113 reduces the thermal stability of hexameric nsp15, while enhancing its EndoU cleavage activity. This EndoU-stimulating mechanism offers an explanation why the virus escapes EPB-113 by becoming EndoU-deficient. Our findings suggest that targeting nsp15 as an antiviral strategy may require a mechanism that alters the conformation of this protein and disrupts its EndoU activity and other functions related to immune evasion and viral replication. Based on the appealing pharmacological profile of EPB-113, we conclude that nsp15 is a challenging but highly relevant drug target.

Microbiology

What problem does this paper attempt to address?

A guanidine-based coronavirus replication inhibitor which targets the nsp15 endoribonuclease and combines a direct antiviral effect with subtle boosting of interferon

Exploration of isatin-based inhibitors of SARS-CoV-2 Nsp15 endoribonuclease

The coronavirus nsp15 endoribonuclease: a puzzling protein and pertinent antiviral drug target

Small-molecule inhibition of SARS-CoV-2 NSP14 RNA cap methyltransferase

A Repurposed Drug Interferes with Nucleic Acid to Inhibit the Dual Activities of Coronavirus Nsp13

Repurposed antibiotic and antiviral drugs inhibit the immune evasive endoribonuclease of SARS-CoV-2 and restrict coronavirus infection in vitro

Dynamic Combinatorial Chemistry Unveils Nsp10 Inhibitors with Antiviral Potential Against SARS‐CoV‐2

Discovery of C-Linked Nucleoside Analogues with Antiviral Activity against SARS-CoV-2

Attacking the SARS-CoV-2 Replication Machinery with the Pathogen Box’s Molecules

Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2

FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms

Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2

The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses

Structure-guided pharmacophore based virtual screening, docking, and molecular dynamics to discover repurposed drugs as novel inhibitors against endoribonuclease Nsp15 of SARS-CoV-2

Targeting papain-like protease for broad-spectrum coronavirus inhibition

Identification of Potential Target Endoribonuclease NSP15 Inhibitors of SARS-COV-2 from Natural Products Through High-Throughput Virtual Screening and Molecular Dynamics Simulation.

Selection of Active Antiviral Compounds Against COVID-19 Disease Targeting Coronavirus Endoribonuclease Nendou/NSP15 Via Ligandbased Virtual Screening and Molecular Docking

Targeting Heparan Sulfate Proteoglycan-Assisted Endocytosis As a COVID-19 Therapeutic Option

Unveiling the Antiviral Capabilities of Targeting Human Dihydroorotate Dehydrogenase against SARS-CoV-2

Discovery of potent SARS-CoV-2 nsp3 macrodomain inhibitors uncovers lack of translation to cellular antiviral response

The small molecule inhibitor of SARS-CoV-2 3CLpro EDP-235 prevents viral replication and transmission in vivo